Esperion Therapeutics, Inc. (NASDAQ:ESPR) Expected to Post Earnings of -$2.74 Per Share

Brokerages expect Esperion Therapeutics, Inc. (NASDAQ:ESPR) to announce earnings per share of ($2.74) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Esperion Therapeutics’ earnings, with the highest EPS estimate coming in at ($2.33) and the lowest estimate coming in at ($3.06). Esperion Therapeutics reported earnings of ($3.89) per share in the same quarter last year, which would suggest a positive year over year growth rate of 29.6%. The company is scheduled to issue its next earnings report on Tuesday, February 22nd.

On average, analysts expect that Esperion Therapeutics will report full-year earnings of ($10.56) per share for the current fiscal year, with EPS estimates ranging from ($10.85) to ($10.09). For the next fiscal year, analysts anticipate that the business will post earnings of ($5.14) per share, with EPS estimates ranging from ($7.95) to ($3.92). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Esperion Therapeutics.

Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Tuesday, November 2nd. The biopharmaceutical company reported ($2.62) earnings per share for the quarter, topping the consensus estimate of ($2.86) by $0.24. During the same quarter in the prior year, the company posted ($3.07) earnings per share.

A number of equities analysts recently weighed in on ESPR shares. Needham & Company LLC dropped their target price on shares of Esperion Therapeutics from $134.00 to $114.00 and set a “strong-buy” rating for the company in a research report on Tuesday, August 3rd. Credit Suisse Group cut Esperion Therapeutics from an “outperform” rating to a “neutral” rating and cut their price target for the company from $28.00 to $11.00 in a report on Monday, October 18th. Cowen decreased their price objective on Esperion Therapeutics from $60.00 to $30.00 and set an “outperform” rating on the stock in a report on Tuesday, October 19th. Morgan Stanley lowered shares of Esperion Therapeutics from an “equal weight” rating to an “underweight” rating and cut their target price for the company from $17.00 to $11.00 in a report on Thursday, October 14th. Finally, JMP Securities reaffirmed a “buy” rating and set a $90.00 price target on shares of Esperion Therapeutics in a research note on Tuesday, September 14th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Esperion Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $40.36.

NASDAQ ESPR opened at $7.69 on Thursday. Esperion Therapeutics has a 12 month low of $6.97 and a 12 month high of $39.49. The stock has a market cap of $223.60 million, a PE ratio of -0.66 and a beta of 0.91. The stock’s 50 day moving average is $10.10 and its 200 day moving average is $15.34.

Hedge funds have recently modified their holdings of the stock. Independent Advisor Alliance purchased a new stake in shares of Esperion Therapeutics during the third quarter valued at $139,000. Royal Bank of Canada increased its position in shares of Esperion Therapeutics by 70.1% during the second quarter. Royal Bank of Canada now owns 6,550 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 2,699 shares during the period. Invesco Ltd. raised its stake in shares of Esperion Therapeutics by 19.2% during the third quarter. Invesco Ltd. now owns 12,667 shares of the biopharmaceutical company’s stock valued at $153,000 after acquiring an additional 2,037 shares in the last quarter. Credit Agricole S A boosted its holdings in shares of Esperion Therapeutics by 49.0% in the second quarter. Credit Agricole S A now owns 7,300 shares of the biopharmaceutical company’s stock valued at $154,000 after purchasing an additional 2,400 shares during the period. Finally, Cetera Advisor Networks LLC grew its stake in Esperion Therapeutics by 29.6% in the third quarter. Cetera Advisor Networks LLC now owns 13,025 shares of the biopharmaceutical company’s stock worth $157,000 after purchasing an additional 2,975 shares in the last quarter. 98.80% of the stock is owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a pharmaceutical company. It engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets.

Featured Story: How does equity income fit into an investing strategy?

Get a free copy of the Zacks research report on Esperion Therapeutics (ESPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.